Abbott
As on 31 Dec, 2025 | 02:29 IST
| Open | 124.43 |
| Previous Close | 124.57 |
| Beta | 0.00 |
| High | 126.20 |
| Low | 124.38 |
| TTM EPS See historical trend | 4.99(+10.40% YoY) |
| 52 Week High | 141.07 |
| 52 Week Low | 110.89 |
| TTM PE See historical trend | 25.21(High PE) |
| Mkt. Cap ($ Billion) | 218.21 |
| Dividend Yield | 1.76 |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 124.99 |
| 10 | 125.76 |
| 20 | 125.12 |
| 50 | 126.27 |
| 100 | 129.42 |
| 200 | 130.1 |
Returns
| 1 Week | 1.02% | |
| 1 Month | -2.40% | |
| 3 Months | -6.08% | |
| YTD | 11.28% | |
| 1 Year | 11.55% | |
| 3 Years | 14.59% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| J&J | 206.95 | -0.29 | 498.70 | 19.94 | 10.38 | 2.83 | 215.04/141.30 | 0.13 | Bullish |
| Thermo Fisher Scientific | 583.60 | -0.25 | 222.53 | 26.05 | 22.40 | 0.36 | 610.77/385.72 | -1.22 | Very Bullish |
| Abbott | 125.81 | 1.00 | 218.21 | 25.21 | 4.99 | 1.76 | 141.07/110.89 | -2.40 | Bearish |
| Intuitive Surgical | 572.68 | -0.47 | 202.99 | 66.51 | 8.61 | -- | 614.58/427.84 | -0.05 | Very Bullish |
| Danaher | 230.70 | 0.03 | 166.63 | 29.92 | 7.71 | 0.67 | 257.66/171.26 | 1.73 | Very Bullish |
Market news
- Dow, S&P 500 close at record highs as Santa rally startsDecember 25, 2025 8:04 AM
- Stocks rise with tech boost, yen weakens after Japan rate hikeDecember 20, 2025 12:20 PM
- Wall Street ends lower; fears of AI bubble and inflation send investors awayDecember 13, 2025 9:01 AM
- Wall Street closes with slight gains as data keeps Fed cut expectations on trackDecember 6, 2025 8:34 AM
About the company
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.